Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity

DocumentFichier
Fichier pdf chargé le 26/03/2019 à 08:06:41
Accès libre
(version éditeur)
fichier
TitreDi-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity
Type de publicationArticle de revue
AuteurBriot, Thomas
1, 2
, Roger, Emilie , Bou Haidar, Naila , Bejaud, Jérôme , Lautram, Nolwenn , Guillet, Catherine , Thepot, Sylvain , Legeay, Samuel , Lagarce, Frédéric
1, 2
EditeurDove Medical Press
TypeArticle scientifique dans une revue à comité de lecture
Année2019
LangueAnglais
Date26 Mars 2019
Pagination2091-2102
Volume14
Titre de la revueInternational Journal of Nanomedicine
ISSN1176-9114
Mots-clésacute myeloid leukemia, decitabine, Lipid nanocapsules, nanomedicines, prodrugs
Résumé en anglais

Background: Acute myeloid leukemia mainly affects adult patients. Complete remission for patients younger than 60 years, who are candidates for standard induction therapy, is achieved in 60%–80% of cases. However, the prognosis is still poor for older patients, who are unfit for intensive chemotherapy, and only a few therapies are available. Hypomethylating agents, such as decitabine, are approved for such patients. The current dosing regimen consists of one administration per day, for 5 days, each 4 weeks.
Methods: Here, we present the synthesis of a decitabine prodrug, combined with its encapsulation into a lipid-based nanocapsule formulation. Decitabine (C12)2 was synthetized, then loaded into nanocapsules. Its stability in phosphate buffer ans human plasma was checked. Its activity was evaluated by Cell proliferation assays and cell-cycle analysis on human erythroleukemia cells. Then its pharmacokinetics was determined on a rat model.
Results: Decitabine (C12)2 was obtained with a yield of 50%. Drug loading into nanocarriers of 27.45±0.05 nm was 5.8±0.5 mg/mL. The stability of decitabine was improved and its activity on leukemia cells was not altered. Finally, pharmacokinetics studies showed a prolonged mean residence time of the drug.
Conclusion: Decitabine (C12)2 as a prodrug showed high encapsulation efficiency, a good stability in plasma with no impact on its activity on leukemia cells and improved pharmacokinetics.

URL de la noticehttp://okina.univ-angers.fr/publications/ua19309
DOI10.2147/IJN.S190482
Lien vers le document

https://www.dovepress.com/di-o-lauroyl-decitabine-lipid-nanocapsules-tow...

Titre abrégéIJN